Anticytokine Therapy, Especially Anti-Interferon-γ, as a Pathogenetic Treatment in TH-1 Autoimmune Diseases

We pioneered anticytokine therapy (ACT) in 1974 and 1989, proposing to remove interferon (IFN) and tumor necrosis factor (TNF)-alpha together with IFNs to treat various autoimmune diseases, including AIDS. This hypothesis was confirmed in different laboratories and opened a new line to produce and test different anticytokines. We have had good, sometimes striking results treating various Th1-mediated autoimmune diseases, including inflammatory skin diseases, using anti-IFN-gamma and sometimes anti-TNF-alpha. Anti-IFN-gamma may be a universal treatment for these conditions. Because TNF-alpha inhibitors, now successfully used in certain autoimmune disorders, have many severe side effects, there are opportunities for the development of other ACT and TNF-alpha antagonists with fewer side effects.